ArticleDisease markers2018
Testing a Combination of Markers of Systemic Redox Status as a Possible Tool for the Diagnosis of Late Onset Alzheimer's Disease.
Article in Disease markers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.
- Serum Uric Acid and the Risk of Dementia: A Systematic Review and Meta-Analysis.Frontiers in aging neuroscience · 2021Pooled it
- The association of serum uric acid with cognitive impairment and ATN biomarkers.Frontiers in aging neuroscience · 2022Article
- Investigation of coenzyme Q10 status, serum amyloid-β, and tau protein in patients with dementia.Frontiers in aging neuroscience · 2022Article
- The Influence of Serum Uric Acid Level on Alzheimer's Disease: A Narrative Review.BioMed research international · 2021Review
- Association of Serum FAM19A5 with Cognitive Impairment in Vascular Dementia.Disease markers · 2020Article
- Responsive Expression of MafF toDisease markers · 2020Article
- Evaluating the link between Paraoxonase-1 levels and Alzheimer's disease development.Minerva medica · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBlood-based parameters reflecting systemic abnormalities associated with typical brain physiopathological hallmarks could be a satisfactory answer to the need of less costly/intrusive and widely available biomarkers for late onset Alzheimer's disease (LOAD). Cumulating evidence from ourselves and others suggests that systemic oxidative stress (OxS) is precociously associated with LOAD. On this basis, we aimed to identify a combination of markers of redox status that could aid the diagnosis of LOAD.
methodsWe reexamined and crossed previous data on 9 serum markers of OxS obtained in a cohort including
resultsA multimarker panel was identified that included significantly increased (hydroperoxides and uric acid) and decreased (thiols, residual antioxidant power, and arylesterase activity) markers. The multivariate model yielded an area under receiver-operating characteristic curve (AUC) of 0.808 for the discrimination between controls and LOAD patients, with specificity and sensitivity of 64% and 79%, respectively.
conclusionsThis study identified a panel of serum markers that distinguish individuals with LOAD from cognitively healthy control subjects. Replication studies on a larger independent cohort are required to confirm and extend our data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.